Exploring Three High Growth Tech Stocks in the United States

The United States market has shown a robust performance, rising 1.5% over the last week and 33% over the past year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in alignment with current market trends.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	20.86%	27.98%	★★★★★★
Sarepta Therapeutics	23.61%	43.75%	★★★★★★
TG Therapeutics	28.39%	43.54%	★★★★★★
Invivyd	42.91%	70.39%	★★★★★★
Ardelyx	27.19%	66.44%	★★★★★★
Amicus Therapeutics	20.33%	62.45%	★★★★★★
Travere Therapeutics	27.18%	69.88%	★★★★★★
MediaAlpha	22.72%	61.31%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 253 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Bitdeer Technologies Group (NasdaqCM:BTDR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Bitdeer Technologies Group is a technology company specializing in blockchain and computing, with a market cap of approximately $1.12 billion.

Operations: Bitdeer Technologies Group generates revenue primarily through its data processing segment, which amounts to $420.89 million.

Bitdeer Technologies Group, recently added to the S&P Global BMI Index, demonstrates a strategic pivot with its advanced AI Training Platform launched by Bitdeer AI. This platform marks a significant enhancement in AI/ML training capabilities, utilizing NVIDIA's high-performance infrastructure which could revolutionize efficiency in developing AI solutions. Despite facing challenges with a decrease in Bitcoin mined—164 this September down from 482 last year—the company is aggressively pursuing growth through innovation and market expansion as evidenced by their recent $10 million share repurchase program and fixed-income offering of $150 million at 8.50%. These moves underscore Bitdeer’s commitment to leveraging technological advancements and financial strategies to position itself strongly within the tech sector.

• Dive into the specifics of Bitdeer Technologies Group here with our thorough health report.

• Review our historical performance report to gain insights into Bitdeer Technologies Group's's past performance.

Amicus Therapeutics (NasdaqGM:FOLD)

Simply Wall St Growth Rating: ★★★★★★

Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and delivery of medicines for rare diseases, with a market capitalization of approximately $3.11 billion.

Operations: Amicus Therapeutics focuses on the discovery, development, and commercialization of advanced therapies for rare diseases, generating revenue of $455.66 million from these activities.

Amicus Therapeutics, amid a dynamic landscape of biotech innovation, underscores its commitment to growth through its significant R&D investments and strategic presence at major healthcare conferences. The company's R&D expenses have facilitated a robust pipeline that is expected to drive revenue growth by 20.3% annually. Recently, Amicus raised its 2024 revenue guidance following a notable reduction in net loss from $43.23 million in Q2 2023 to $15.7 million in Q2 2024, reflecting improved operational efficiency and effective cost management strategies. These efforts are complemented by their active engagement with the global medical community, as seen at events like the Society for the Study of Inborn Errors of Metabolism Symposium and Morgan Stanley’s Global Healthcare Conference, which may enhance their industry standing and foster future collaborations.

• Delve into the full analysis health report here for a deeper understanding of Amicus Therapeutics.

• Evaluate Amicus Therapeutics' historical performance by accessing our past performance report.

Krystal Biotech (NasdaqGS:KRYS)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing genetic medicines for patients with rare diseases in the United States, with a market cap of $5.13 billion.

Operations: Krystal Biotech specializes in genetic medicines targeting rare diseases, operating within the biotechnology sector. The company is currently in the commercial stage, focusing on bringing its innovative therapies to market in the United States.

Krystal Biotech stands out in the biotech sector with a projected annual revenue growth of 33%, significantly outpacing the US market average of 8.8%. This growth is supported by an impressive anticipated earnings increase of 34.2% per year, highlighting the company's effective strategy and operational efficiency. Recent presentations at high-profile healthcare conferences, coupled with positive interim results from their PEARL-1 clinical trials, underscore Krystal's commitment to innovation and market leadership in gene therapy solutions. Their recent transition to profitability marks a pivotal milestone, reflecting robust financial health and strategic execution that could shape future industry standards.

• Click to explore a detailed breakdown of our findings in Krystal Biotech's health report.

• Learn about Krystal Biotech's historical performance.

Seize The Opportunity

• Discover the full array of 253 US High Growth Tech and AI Stocks right here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com